共查询到20条相似文献,搜索用时 62 毫秒
1.
自微乳化释药系统是由油相、表面活性剂、助表面活性剂和药物组成的澄清、均一的液体或者固体制剂,是一种脂质给药系统。目前,很多药物在生物体内溶解度比较小,因此,如何增加药物的溶解度,提高生物利用度是西药制剂中的一大难题。本文对自微乳化释药系统的作用机制、处方研究以及在难溶性西药制剂中的应用作一综述。 相似文献
2.
3.
4.
5.
很多新活性药物在生物体内溶解度很小,如何增加药物溶解度,提高其生物利用度是药物制剂工作中的一大难题.本文介绍了自微乳化释药系统的基本概述,并对其在难溶性西药制剂中的应用进行综述. 相似文献
6.
7.
自乳化释药系统的探讨 总被引:1,自引:0,他引:1
自乳化药物传递系统可改善药物的口服吸收,增加其生物利用度,是克服某些脂溶性或水难溶性药物制剂吸收困难的一种极具潜力的方法,本文从自乳化释药系统的基本概念、处方设计、质量评价等方面出发,对其在药学方面应用的特殊及质量要求等进行讨论。 相似文献
8.
自乳化给药系统因可提高药物的吸收速度和程度,增强难溶性药物的溶解能力,提高生物利用度而成为当前药剂研究的一大热点。本综述就近几年国内外关于自乳化给药系统的最新研究进展作一简要介绍。 相似文献
9.
10.
自乳化释药系统的应用 总被引:2,自引:0,他引:2
王莘 《中国医院药学杂志》2007,27(3):375-377
目的:介绍自乳化释药系统的应用。方法:通过查阅文献,综述自乳化释药系统。结果:自乳化释药系统可提高药物吸收速度和程度,从而提高药物的生物利用度。结论:自乳化释药系统属于热力学稳定体系,克服了乳剂久置必分层的缺点,便于贮存,此外,自乳化制剂给药方便,工艺简单,因此逐渐成为药剂学研究的重要领域。 相似文献
11.
Yanagihara K 《Current pharmaceutical design》2002,8(6):475-482
Liposome-encapsulated drugs often exhibit reduced toxicity and have also been shown to enhance retention of drugs in the tissues. Thus, encapsulation of drugs in liposomes has often resulted in an improved overall therapeutic efficacy. The results of efficacy of liposome-encapsulated ciplofloxacin or azithromycin for therapy of intracellular M. avium infection show enhanced cellular delivery of liposome-encapsulated antibiotics and suggest that efficiency of intracellular targeting is sufficient to mediate enhanced antimycobacterial effects. The antitubercular drugs encapsulated in lung specific stealth liposomes have enhanced efficacies against tuberculosis infection in mice. These results from stealth liposome study indicate that antitubercular drugs encapsulated in liposome may provide therapeutic advantages over the existing chemotherapeutic regimen for tuberculosis. Liposomes with encapsulated amikacin are able to protect collagen almost completely from adherence of bacterial cells of all strains examined and prevent from invading of bacteria. 相似文献
12.
13.
Olivier Barrière Jun Li Fahima Nekka 《Journal of pharmacokinetics and pharmacodynamics》2013,40(1):41-52
Since drug related variability arises from different origins, particularly driven by the behaviour or physiology of the patient, the problems of drug intake and drug disposition are separately presented in general. To overcome the potential drawbacks of this artificial split, we propose in this paper a combined illustrative approach, named compliance spectrum, such that these two subprocesses can be equitably studied and visualized. We construct the compliance spectrum based on the Bayesian decision method we previously developed for the inverse problem of patient compliance within the framework of Population-PK. This spectrum provides an intuitive and interactive way to evaluate the relationship between drug intake and drug disposition along with their consequences on PK profile. As well, it opens a new direction for model quality diagnostic. 相似文献
14.
15.
Rats were trained to discriminate norfenfluramine (NF) 1.4 mg/kg from its vehicle or amphetamine (AMPH) 0.8 mg/kg or pentobarbital (PB) 6.0 mg/kg in order to determine the role that drug combination training plays in the rate of learning and sensitivity to lower drug doses. The results suggest that drug versus drug training can increase the rate of drug discrimination learning for some drugs that are learned slowly when trained in a drug versus vehicle training procedure, whereas drug versus drug training does not increase the rate of learning for other drugs that are learned rapidly. Drug versus drug training does, however, appear to increase the level of stimulus control of the training drug for all drugs examined in this study. 相似文献
16.
Blackburn JL 《PharmacoEconomics》1993,3(1):14-21
Drug use review (DUR) programmes have been a component of efforts to improve prescribing practices in both the institutional and ambulatory care settings in various areas of the world. DUR provides the mechanism for developing standards, assessing current therapy, and implementing a specific intervention followed by reassessment of drug utilisation. A number of interventions aimed at improving drug prescribing practices have been included as components of the DUR process. At this time, face-to-face interaction with the prescriber has been shown to be the most effective intervention. However, DUR interventions have rarely been subjected to quality pharmacoeconomic evaluation. There is a need for future research to evaluate the effects of DUR programmes on overall healthcare outcomes. 相似文献
17.
18.
Two groups of pigeons with a history of two choice operant drug discrimination tasks (3.0 mg/kg morphine versus 5.6 mg/kg cocaine, and 3.0 mg/kg morphine versus 3.0 mg/kg cocaine, respectively; Swedberg and Järbe 1985) were subjected to three choice tasks in which responses on a third manipulandum were reinforced in the no drug condition. Training drugs generalization gradients in both groups were similar to those normally obtained in two choice drug versus no drug tasks. The salience differences between the training stimuli within the groups observed in the previous two choice task did not differentially affect the three choice discrimination gradients. Tests with novel drugs after the introduction of the no drug condition yielded increased responding to the no drug condition with the exception of the dopamine agonist apomorphine. Results are discussed in terms of a discrimination learning model specifying principles of relative discriminative stimulus control in various discrimination cases.Portions of these data were presented at the International Union of Pharmacology, IUPHAR, 9th International Congress of Pharmacology Satellite Meeting: European Study Group for Internal Stimulus Control by Electrical Stimulation, Drugs and Other Means, ESISC, London, July 29–August 3, 1984 (Swedberg and Järbe 1984). An earlier version of this work appears in the doctoral thesis by the first author (Swedberg 1985). 相似文献
19.
20.
Bimal Malhotra Richard Sachse Nolan Wood 《European journal of clinical pharmacology》2009,65(6):551-560
Purpose To assess drug–drug interactions of fesoterodine with cytochrome P450 (CYP) 3A4 inhibitor (ketoconazole), inducer (rifampicin),
and substrates (ethinylestradiol and levonorgestrel).
Methods Effects of ketoconazole 200 mg twice daily and rifampicin 600 mg twice daily on fesoterodine 8 mg once daily were investigated
in CYP2D6 extensive metabolizers (EMs) and poor metabolizers (PMs) based on 5-hydroxymethyl tolterodine (5-HMT) pharmacokinetics
(principal active fesoterodine metabolite and CYP3A4 substrate). Effects of fesoterodine 8 mg versus placebo once daily on
ethinylestradiol and levonorgestrel were investigated based on oral contraceptive pharmacokinetics and on pharmacodynamic
effects on progesterone, luteinizing hormone, follicle-stimulating hormone, and estradiol plasma levels.
Results Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum
concentration in plasma (Cmax; from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve
(AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs). Coadministration of festerodine with rifampicin
resulted in decreases in mean 5-HMT Cmax (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8
to 19.6 ng h/mL in PMs). Fesoterodine did not affect oral contraceptive pharmacokinetics or pharmacodynamics or the suppression
of ovulation.
Conclusions Fesoterodine dosage should not exceed 4 mg once daily when taken concomitantly with potent CYP3A4 inhibitors. Coadministration
of CYP3A4 inducers with fesoterodine may produce subtherapeutic 5-HMT exposures. No dose adjustment is necessary for concomitant
use of fesoterodine with oral contraceptives.
Funding for this study was provided by Schwarz Biosciences GmbH, and Pfizer Inc. 相似文献